

### 4eme Congrès Société de Physiologie et Biologie intégrative

2 - 4 Septembre 2021, Faculté de Médecine NICE – France

## Clinical Pathogenicity Prediction Of Histone 3 Family Component With An *In-silico* Screening Of H3.3A Gene In Human

<u>Nawel Souad Halfaoui</u> <sup>1, 2</sup>, M Dali-Youcef <sup>2</sup>, Houssam Boulenouar <sup>1</sup>, N Denouni <sup>2</sup>, Y Harek <sup>2</sup>


<sup>1</sup> Cancer lab\_ Université de Tlemcen, Tlemcen, Algérie, <sup>2</sup> Analytical chemistry and Electrochemistry Lab, Tlemcen, Algérie

#### **Contact:**

Email: <u>halfaouisouad@gmail.com</u> LinkedIn: <u>https://www.linkedin.com/in/nawal-souad-halfaoui/</u> Phone: (+213) 558 457 408

Background

Histone variant H3.3 is a member of human histone H3 family, it is expressed in whole cell cycle phases. H3.3 histone is encoded by two genes named H3.3A (H3F3A) and H3.3B (H3F3B) located on **chromosome 1** and **chromosome 17** respectively [1-3]



Several studies have shown the possible role of histones methylation and acetylation with cancer [4], but none have investigated the potential role and consequences of those genetic variations

The goal of the present study is to explored different SNP variations in H3.3A gene and pathogenetic variations.

**Figure1** Schematic drawing of a nucleosome with the four canonical histones (H3, H4, H2A, and H2B)

# Methods

Ensembl, dbSNP NCBI[5], and Uniprot databases were used to collect gene We compared scores and prediction with 4 different software; SIFT,Polyphen-2, information.
REVEL, and MUTATION-Assesor.

To evaluate the pathological nature of those variations, we selected 19 SNVs from 10 transcripts of the gene.

# Results

After checking all the transcripts and • exons, we compared 19 SNP (table1)

 The SIFT score SIFT score consider a mutation from 0.0 as (deleterious) and to 1.0 as (tolerated). This method shows that 18 SNVs are considered to be deleterious. The levels of probably damaging • and possibly damaging were classified as functionally significant ( $\leq 0.5$ ) and the benign level being classified as tolerated ( $\geq 0.51$ ) with PolyPhen-2, and in this study, it does only considered 13 SNPs as Probably damaging and 1 as Possibly damaging

**Table 1:** Summary of damaging mutations comminating different software

SNP ID	A.A replace ment	SIFT		Polyphen-2		Revel		MUTATION- ASSESOR	
		Predictio n	Score	Prediction	Score	Predictio n	Score	Predicti on	Score
rs53253160 0	L/R	Damagin g	0	Probably damagin g	0.999	likely disease causing	0.874	Mediu m	0.91
rs14643068 89	K/E	Damagin g	0	Probably damagin g	0.981	likely disease causing	0.685	High	0.977
rs76711356 2	Q/H	Damagin g	0.01	Probably damagin g	0.996	likely disease causing	0.874	Mediu m	0.91

REVEL Scores above 0.5, as
'likely disease causing' and display scores below 0.5 as 'likely benign, and this tool considered 7 SNPs as
likely diseases causing. For Mutation-ASSESOR, the score is one of 'neutral', 'low', 'medium' and 'high', and the rank score, which is between 0 and 1 where variants with higher scores are more likely to be deleterious, and our results show only 2 SNPs as deletirous.

SIFT

Pathogenic

**SNVs** 

Mutation-ASSESOR

**Figure 3** : 3

clinically damaging


mutations identified

by 4 tools

REVEL


PolyPhen

Combining results of all methods, only 3 mutations appear to be *clinically damaging*, with a change from hydrophobic to hydrophile amino acid in only one mutation.



#### Conclusion

The present study shows combination of different softwares by an *in-silico* approach, to define most diseases-associated mutations, in the H3-3A gene. Protein prediction methods are recommended to a better understanding of structures and function.



#### Figure 2:

The crystal structure of the nucleosome containing histone H3.3 (in green)

#### References

- 1. Jang CW, Shibata Y, Starmer J, et al. Histone H3.3 maintains genome integrity during mammalian development. Genes Dev 2015;29:1377-92.
- Frank D, Doenecke D, Albig W. Differential expression of human replacement and cell cycle dependent H3 histonegenes. Gene 2003;312:135-43.
- Albig W, Bramlage B, Gruber K, et al. The human replacement histone H3.3B gene (H3F3B). Genomics 1995;30:264-72.
- 4. Cairns J. Mutation selection and the natural history of cancer. Nature. 1975;255:197–200.
- 5. S.T.Sherry, M.-H.Ward, M. Kholodov et al., "DbSNP: the NCBI database of genetic variation," Nucleic Acids Research, vol. 29, no. 1, pp. 308–311, 2001.